HTA Evolution & Access Pressures

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning, especially the CMS Part D implementation piece.

MarcusSame here. We're looking at CMS Part D Redesign Implementation Challenges — the operational hurdles are becoming clearer as we move into the second half of the year. Then ICER Alzheimer's Evidence Report with New Endpoints — the inclusion of real-world data in value assessments is a significant shift. And EMA Rare Disease Adaptive Pathway Expansion — the expansion could reshape evidence generation for rare diseases. Finally, FDA Breakthrough Therapy Designation Update for Gene Therapies — the update aims to accelerate development for high-need areas.

SaraThat second one is interesting to me — the integration of new endpoints in Alzheimer's assessments is a complex methodological shift that payers will be watching closely for budget impact implications.

MarcusExactly. Let's get into it.

MarcusThe CMS Part D redesign is now facing operational hurdles as the implementation progresses. The shift to enhanced rebates and the introduction of inflation rebates are causing significant administrative burdens for plans and PBMs. The complexity of the new model is leading to uncertainty in formulary placement and patient access.

SaraAnd what strikes me about that is the budget impact for payers. The administrative costs are substantial, but the real concern is the potential for increased premiums and reduced plan participation, which could undermine the goals of the redesign.

MarcusThat's fair, though I think the long-term sustainability is the key here. CMS is pushing for more value-based purchasing, but the transition is messy. The industry is struggling with the new reporting requirements and the timing of rebates.

SaraI'd push back slightly on that — the administrative burden is one thing, but the budget impact on Medicare Advantage plans is another. They're facing higher costs without clear evidence of improved patient outcomes, which is a classic value assessment challenge.

MarcusThat connects to something I keep coming back to: the tension between policy intent and operational reality. The redesign was meant to lower costs, but the implementation is creating new inefficiencies. The industry is now asking for more flexibility in the timelines.

SaraThe part that gives me pause is the impact on patient access. If plans become more cautious about covering innovative therapies due to the financial uncertainty, that could lead to delays in access for beneficiaries.

MarcusExactly, and from the payer side, the opportunity cost is significant. The resources spent on navigating the redesign could be redirected to other areas of patient care.

SaraThis is one of those stories where the policy is sound but the execution is falling short. We'll be watching how CMS responds to the industry feedback.

MarcusICER's latest Alzheimer's evidence report is incorporating new endpoints, including real-world data and patient-reported outcomes. This shift reflects a broader trend toward more holistic value assessments in neurodegenerative diseases.

SaraI wonder if that's the full picture though. While including new endpoints is important, the methodological challenges in using real-world data for Alzheimer's are substantial. The noise in the data and the lack of standardized measures could undermine the reliability of the assessments.

MarcusThat's one read — I'd frame it slightly differently. The inclusion of real-world data is a necessary evolution given the limitations of traditional endpoints in capturing the patient experience. The industry has been pushing for this for years.

SaraThe part that gives me pause is the budget impact. If the new endpoints lead to more favorable assessments for high-cost therapies, the system sustainability could be at risk. Payers are already struggling with the cost of Alzheimer's treatments.

MarcusThat's fair, though I think payers would see it differently. The shift toward patient-centered value assessments is long overdue. The key is ensuring the new endpoints are validated and reliable.

SaraI keep coming back to the operational challenges. How do HTA bodies integrate these new endpoints into their existing frameworks without causing delays in assessments?

MarcusThis is one of those stories where the trend is clear but the implementation is complex. The industry will need to invest in generating high-quality real-world evidence to support these new approaches.

SaraAgreed. The next step will be to see how other HTA bodies adapt their methodologies in response.

MarcusThe EMA has expanded its adaptive licensing pathway for rare diseases, aiming to accelerate patient access to promising therapies. The expansion includes more flexibility in trial design and earlier conditional approvals.

SaraThat's interesting — the adaptive pathway is a positive step, but the challenge will be in the post-marketing evidence requirements. If the expansion leads to more conditional approvals without robust post-marketing data, the long-term value for patients and payers could be questionable.

MarcusI'd push back slightly on that. The adaptive pathway is designed to address the high unmet need in rare diseases, and the expansion is a response to the limitations of traditional development pathways. The industry has been advocating for more flexibility.

SaraThe part that gives me pause is the budget impact. If more therapies reach the market with less evidence, payers may face higher costs without clear evidence of long-term benefits. The opportunity cost is significant.

MarcusThat's one read — I'd frame it differently. The adaptive pathway allows for earlier access, which is crucial for patients with rare diseases. The post-marketing requirements are designed to ensure ongoing evaluation.

SaraI wonder if that's the full picture though. The expansion could lead to a flood of applications, overwhelming the EMA's resources and potentially compromising the quality of assessments.

MarcusThis is one of those stories where the intention is good but the execution is complex. The industry will need to work with regulators to ensure the pathway is used responsibly.

SaraAgreed. We'll be watching how the expansion impacts the development landscape for rare diseases.

MarcusThe FDA has updated its breakthrough therapy designation for gene therapies, aiming to accelerate development for high-need areas. The update includes more frequent interactions with sponsors and streamlined review processes.

SaraWhat strikes me about that is the potential for earlier access but also the risk of accelerated approvals without sufficient evidence. The FDA's focus on gene therapies is understandable given their transformative potential, but the bar for breakthrough designation needs to remain high.

MarcusThat's fair, though I think the industry would see it as a positive step. The update reflects the recognition that gene therapies require different development pathways. The FDA is trying to balance speed with safety.

SaraI'd push back slightly on that. The concern is that the expanded designation could lead to more accelerated approvals without robust evidence, which could undermine confidence in the pathway. The budget impact for payers could be significant.

MarcusThat's one read — I'd frame it differently. The update is about providing more support for sponsors developing innovative therapies. The FDA is emphasizing the importance of patient input in the designation process.

SaraThe part that gives me pause is the methodological challenges in evaluating gene therapies. The long-term data is often lacking, and the endpoints may not capture the full clinical benefit.

MarcusThis is one of those stories where the trend is toward more flexibility but the evidence requirements must remain rigorous. The industry will need to generate high-quality data to support these therapies.

SaraAgreed. The next step will be to see how the FDA implements the update in practice.

SaraA lot to think about today. I'll be watching how CMS responds to the Part D redesign operational challenges and whether they adjust the timelines to reduce the burden.

MarcusSame — and for me the thread running through today is the tension between accelerated access and robust evidence generation, especially in rare diseases and gene therapies.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.